Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lundgren

Showing results (551-560 of 681) with videos related to

Pageof 69
Sort By:
AIDS (London, England)|May 11, 2010
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study, Colette Smith, Caroline A Sabin, et al.
The Journal of Infectious Diseases|December 29, 2022
Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIVCavan S Reilly, Álvaro H Borges, Jason V Baker, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 31, 2020
Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantationChristina Ekenberg, Caspar da Cunha-Bang, Isabelle P Lodding, et al.
HIV Medicine|January 22, 2003
Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) studyM Law, N Friis-Møller, R Weber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?, Amanda Mocroft, Peter Reiss, et al.
Circulation|February 4, 2009
Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)Signe W Worm, Stephane De Wit, Rainer Weber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2013
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D studyCaroline A Sabin, Lene Ryom, Helen Kovari, et al.
The Journal of Infectious Diseases|January 7, 2012
Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic strokeS W Worm, D A Kamara, P Reiss, et al.
Plos One|December 7, 2013
The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trialMaria Egede Johansen, Jens-Ulrik Jensen, Morten Heiberg Bestle, et al.
BMC Medicine|April 3, 2016
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaborationCaroline A Sabin, Peter Reiss, Lene Ryom, et al.
Pageof 69

Showing results (551-560 of 681) with videos related to

Sort By:
Pageof 69
AIDS (London, England)|May 11, 2010
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study, Colette Smith, Caroline A Sabin, et al.
The Journal of Infectious Diseases|December 29, 2022
Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIVCavan S Reilly, Álvaro H Borges, Jason V Baker, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 31, 2020
Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantationChristina Ekenberg, Caspar da Cunha-Bang, Isabelle P Lodding, et al.
HIV Medicine|January 22, 2003
Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) studyM Law, N Friis-Møller, R Weber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?, Amanda Mocroft, Peter Reiss, et al.
Circulation|February 4, 2009
Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)Signe W Worm, Stephane De Wit, Rainer Weber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2013
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D studyCaroline A Sabin, Lene Ryom, Helen Kovari, et al.
The Journal of Infectious Diseases|January 7, 2012
Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic strokeS W Worm, D A Kamara, P Reiss, et al.
Plos One|December 7, 2013
The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trialMaria Egede Johansen, Jens-Ulrik Jensen, Morten Heiberg Bestle, et al.
BMC Medicine|April 3, 2016
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaborationCaroline A Sabin, Peter Reiss, Lene Ryom, et al.
Pageof 69